Navigation Links
Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17
Date:8/12/2011

SAN DIEGO, Aug. 12, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Wedbush 2011 Life Sciences Conference in New York. The presentation is scheduled for Wednesday, August 17 at 9:10 a.m. EDT (6:10 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. A replay will be available for 90 days after the event.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com.

Halozyme Contact
Kurt Gustafson
Chief Financial Officer
(858) 704-8272
kgustafson@halozyme.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
2. Halozyme and Intrexon Announce Collaboration to Develop First Subcutaneous Recombinant Alpha 1-Antitrypsin Replacement Therapy
3. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
4. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
5. Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12
6. Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6
7. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
8. Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11
9. Halozyme Therapeutics to Present at J.P. Morgan Healthcare Conference on January 12
10. Halozyme Therapeutics Realigns Management
11. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)...  The particle counters market is projected to ... 275.9 million in 2016, at a CAGR of ... http://www.reportlinker.com/p04718602-summary/view-report.html The growing pharmaceutical and ... growth in manufacturing industries in emerging nations are ... counters. On the other hand, technical limitations of ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... , ... February 24, 2017 , ... The Radiology ... excellence in radiology marketing programs at the annual Building Better Radiology Marketing Programs ... Fort Worth Hotel in Fort Worth, Texas. Nine awards are given out in five ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations ... International Elite division on February 12th. Ms. Esparza qualified into this prestigious ... qualifier competition held in Las Vegas, Nevada. Frida is one of approximately 25 ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the ... The Jensie Gran Fondo of Marin. For the second year in a row, ... mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... The 89th ... the winner of the 2016 National Education Policy Center Bunkum Award. We invite you ... in 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), ...
Breaking Medicine News(10 mins):